SAN DIEGO — The recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children with rheumatic diseases, all within the past 4 years, have changed the landscape in pediatric rheumatology, noted a speaker here. “Pediatric indications are always delayed,” Hermine Brunner, MD, MSc, MBA, of the University of Cincinnati…Read More
Multiple recent FDA approvals in pediatric rheumatology overcome delayed trials
